Viridian Therapeutics (VRDN) Projected to Post Earnings on Thursday

Key Points

• Viridian Therapeutics (NASDAQ: VRDN) is scheduled to release its Q2 2025 earnings results on August 14th, with analysts expecting earnings of (1.01) per share and revenues of $0.05 million.
• The company's previous quarter saw a reported EPS of (1.00), meeting expectations, with revenues slightly above estimates at $0.08 million.
• Wall Street maintains a consensus rating of "Moderate Buy" for VRDN, with target prices ranging from $27.00 to $38.00.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect Viridian Therapeutics to post earnings of ($1.01) per share and revenue of $0.05 million for the quarter.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 72.85%. The business had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.05 million. During the same quarter in the previous year, the firm posted ($0.81) EPS. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Stock Performance

VRDN stock traded down $0.12 during midday trading on Friday, reaching $16.41. 879,632 shares of the company's stock traded hands, compared to its average volume of 702,380. The company has a 50-day moving average price of $15.95 and a two-hundred day moving average price of $15.21. The company has a debt-to-equity ratio of 0.05, a quick ratio of 19.49 and a current ratio of 19.49. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $27.20. The firm has a market capitalization of $1.34 billion, a PE ratio of -4.28 and a beta of 0.42.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its holdings in shares of Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company's stock worth $16,595,000 after purchasing an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Viridian Therapeutics by 12.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company's stock worth $1,760,000 after acquiring an additional 14,788 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company's stock worth $669,000 after acquiring an additional 876 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in Viridian Therapeutics in the second quarter worth $187,000. Finally, Creative Planning purchased a new position in Viridian Therapeutics in the second quarter worth $179,000.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Needham & Company LLC lowered their target price on shares of Viridian Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Wednesday. The Goldman Sachs Group boosted their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday. Wells Fargo & Company lowered their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an "equal weight" rating on the stock in a report on Thursday. Royal Bank Of Canada lowered their target price on shares of Viridian Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a report on Thursday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $37.00.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.